Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
Jun 07 04:00PM ET
0.3718
Dollar change
+0.0208
Percentage change
5.93
%
Index- P/E- EPS (ttm)-0.48 Insider Own42.71% Shs Outstand128.42M Perf Week13.01%
Market Cap47.75M Forward P/E- EPS next Y-0.26 Insider Trans-0.11% Shs Float73.58M Perf Month-4.64%
Income-48.81M PEG- EPS next Q-0.07 Inst Own5.95% Short Float0.28% Perf Quarter-25.64%
Sales0.62M P/S77.02 EPS this Y36.52% Inst Trans11.31% Short Ratio0.25 Perf Half Y-7.05%
Book/sh0.03 P/B11.20 EPS next Y12.18% ROA-114.91% Short Interest0.21M Perf Year-64.92%
Cash/sh0.22 P/C1.71 EPS next 5Y- ROE-3702.24% 52W Range0.25 - 1.09 Perf YTD25.35%
Dividend Est.- P/FCF- EPS past 5Y-18.22% ROI-303.78% 52W High-65.89% Beta0.45
Dividend TTM- Quick Ratio1.22 Sales past 5Y50.93% Gross Margin-232.58% 52W Low48.72% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.23 EPS Y/Y TTM-15.29% Oper. Margin-6296.77% RSI (14)53.43 Volatility14.79% 12.26%
Employees85 Debt/Eq7.62 Sales Y/Y TTM12.73% Profit Margin-7873.23% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq2.77 EPS Q/Q44.25% Payout- Rel Volume1.62 Prev Close0.35
Sales Surprise-55.08% EPS Surprise-12.50% Sales Q/Q-31.78% EarningsMay 08 BMO Avg Volume841.48K Price0.37
SMA203.48% SMA50-0.43% SMA200-16.15% Trades Volume1,366,099 Change5.93%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Downgrade Oppenheimer Outperform → Perform
Jul-18-22Initiated H.C. Wainwright Buy $16
May-02-22Initiated Canaccord Genuity Buy $10
Sep-28-21Initiated Oppenheimer Outperform $20
Jun-05-24 08:00AM
May-28-24 07:30AM
May-14-24 08:00AM
May-10-24 07:30AM
May-08-24 12:54PM
08:55AM Loading…
08:55AM
08:00AM
06:00AM
May-01-24 08:30AM
Apr-16-24 04:01PM
Mar-19-24 08:30AM
Mar-15-24 08:00AM
Mar-13-24 09:30AM
08:00AM
Mar-07-24 08:00AM
08:00AM Loading…
Feb-29-24 08:00AM
Feb-22-24 08:00AM
Feb-05-24 02:30PM
Jan-24-24 08:30AM
Jan-10-24 09:00AM
Jan-08-24 07:00AM
Jan-03-24 04:25PM
Dec-22-23 03:00PM
Dec-21-23 07:46AM
07:00AM
07:00AM
Dec-19-23 09:00AM
Dec-15-23 03:00PM
Dec-14-23 08:36AM
Dec-12-23 08:30AM
02:19PM Loading…
Dec-08-23 02:19PM
Nov-23-23 09:00AM
Nov-14-23 08:30AM
Nov-09-23 09:00AM
Nov-07-23 08:57AM
08:00AM
Oct-31-23 08:30AM
Oct-26-23 08:30AM
Oct-19-23 08:30AM
Oct-17-23 08:30AM
Oct-11-23 09:00AM
Oct-06-23 02:15PM
Oct-05-23 10:00AM
Sep-29-23 03:00PM
08:30AM
Sep-28-23 08:00AM
Sep-27-23 09:00AM
Sep-25-23 04:00PM
07:00AM
Aug-30-23 08:20AM
Aug-29-23 07:00AM
Aug-14-23 08:00AM
Aug-02-23 07:00AM
Jun-28-23 11:19AM
07:13AM
Jun-26-23 08:00AM
Jun-21-23 09:20AM
07:20AM
Jun-16-23 08:00AM
Jun-15-23 04:38PM
04:29PM
07:00AM
May-25-23 08:00AM
May-12-23 04:00PM
Apr-25-23 04:05PM
Apr-11-23 08:00AM
Mar-16-23 09:46AM
Mar-13-23 07:00AM
Mar-09-23 06:30AM
Mar-08-23 04:10PM
Mar-07-23 08:00AM
Mar-06-23 07:00AM
Feb-27-23 07:00AM
Feb-13-23 07:00AM
Jan-11-23 08:00AM
Dec-27-22 04:01PM
Dec-12-22 08:00AM
Nov-28-22 08:00AM
Nov-07-22 08:00AM
Oct-31-22 08:00AM
Oct-03-22 08:00AM
Sep-30-22 04:12PM
Sep-21-22 07:00AM
Aug-30-22 07:00AM
Aug-15-22 07:00AM
07:00AM
Aug-12-22 04:01PM
Jul-19-22 07:00AM
Jul-14-22 07:00AM
Jun-27-22 07:00AM
Jun-02-22 07:00AM
Jun-01-22 07:00AM
May-19-22 07:30AM
May-16-22 08:00AM
May-09-22 08:00AM
May-04-22 11:29AM
Apr-01-22 07:00AM
Mar-14-22 07:00AM
Mar-11-22 07:00AM
Mar-03-22 07:00AM
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
General Resonance LLC10% OwnerMay 01 '24Sale0.4013,0005,14815,313,712May 08 12:16 PM
General Resonance LLC10% OwnerApr 30 '24Sale0.4213,0005,41615,326,712May 08 12:16 PM
General Resonance LLC10% OwnerApr 24 '24Sale0.3310,0003,27815,349,712May 01 05:13 PM
General Resonance LLC10% OwnerApr 09 '24Sale0.3922,5008,67415,428,212Apr 16 09:38 AM
MATLIN DAVID JDirectorNov 10 '23Buy0.41250,002102,5017,043,686Nov 13 07:48 AM
Stevens John HenryDirectorJun 26 '23Buy0.80316,455253,164800,204Jun 27 02:13 PM
Etherington Robert DeeChief Executive OfficerJun 26 '23Buy0.8125,00020,25025,000Jun 27 08:07 AM
Ugwumba ChidozieResigned as director 2/15/2023Jun 16 '23Buy0.807,500,0006,000,00013,018,908Sep 08 04:33 PM
Mosca AlisonDirectorJun 16 '23Buy0.802,394,3751,915,5003,238,375Jun 20 11:02 AM
MATLIN DAVID JDirectorJun 16 '23Buy0.801,500,0001,200,0006,793,684Jun 20 07:57 AM
Gay JonathonDirectorJun 16 '23Buy0.80105,62584,500105,625Jun 20 09:50 AM
Last Close
Jun 07 04:00PM ET
0.3507
Dollar change
-0.0194
Percentage change
-5.24
%
Index- P/E- EPS (ttm)-0.65 Insider Own79.46% Shs Outstand45.98M Perf Week-12.33%
Market Cap24.48M Forward P/E- EPS next Y-0.31 Insider Trans-0.04% Shs Float14.34M Perf Month-4.86%
Income-37.13M PEG- EPS next Q-0.09 Inst Own0.19% Short Float3.65% Perf Quarter-17.85%
Sales0.00M P/S- EPS this Y3.92% Inst Trans-0.13% Short Ratio1.18 Perf Half Y20.64%
Book/sh-0.16 P/B- EPS next Y36.73% ROA-60.38% Short Interest0.52M Perf Year-1.54%
Cash/sh0.63 P/C0.55 EPS next 5Y- ROE-190.33% 52W Range0.19 - 0.86 Perf YTD25.25%
Dividend Est.- P/FCF- EPS past 5Y-28.31% ROI-115.99% 52W High-58.98% Beta1.35
Dividend TTM- Quick Ratio4.40 Sales past 5Y0.00% Gross Margin- 52W Low87.94% ATR (14)0.05
Dividend Ex-Date- Current Ratio4.40 EPS Y/Y TTM25.22% Oper. Margin0.00% RSI (14)46.13 Volatility9.47% 13.77%
Employees71 Debt/Eq0.44 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.17
Option/ShortNo / Yes LT Debt/Eq0.40 EPS Q/Q-40.51% Payout- Rel Volume0.34 Prev Close0.37
Sales Surprise- EPS Surprise-300.00% Sales Q/Q- EarningsMay 21 BMO Avg Volume443.69K Price0.35
SMA20-3.94% SMA50-3.06% SMA2006.97% Trades Volume152,083 Change-5.24%
Date Action Analyst Rating Change Price Target Change
Apr-15-21Initiated Ladenburg Thalmann Buy $25
May-30-24 04:50PM
07:00AM
May-21-24 06:30AM
May-15-24 07:00AM
May-06-24 07:00AM
08:00AM Loading…
Apr-23-24 08:00AM
Apr-18-24 08:00AM
Apr-05-24 09:55AM
Apr-04-24 07:49AM
Apr-03-24 06:30AM
Mar-27-24 06:30AM
Mar-19-24 05:00AM
Mar-18-24 06:30AM
Mar-06-24 07:30AM
Jan-04-24 08:00AM
04:15PM Loading…
Nov-30-23 04:15PM
Nov-29-23 06:30AM
Nov-14-23 06:30AM
Oct-27-23 08:00AM
Oct-18-23 08:00AM
Oct-04-23 06:34AM
Sep-07-23 09:00AM
Sep-06-23 04:05PM
Aug-09-23 06:30AM
Aug-02-23 04:30PM
Jun-08-23 05:00PM
May-31-23 03:00AM
May-15-23 06:30AM
May-12-23 08:00AM
May-08-23 06:30AM
06:30AM Loading…
May-05-23 06:30AM
Mar-29-23 06:30AM
Mar-27-23 07:00AM
Feb-22-23 06:35AM
06:30AM
Nov-29-22 09:10AM
Nov-09-22 06:30AM
Nov-02-22 09:00AM
Sep-11-22 07:22AM
Aug-10-22 06:30AM
Aug-07-22 03:17AM
Aug-04-22 11:20AM
Jul-06-22 01:45AM
Jun-28-22 06:30AM
Jun-27-22 06:30AM
May-24-22 01:52AM
May-20-22 08:00AM
May-11-22 06:30AM
May-06-22 07:00AM
May-05-22 08:00AM
Mar-30-22 06:30AM
Mar-23-22 08:00AM
Feb-24-22 08:00AM
Jan-04-22 07:00AM
Nov-17-21 08:00AM
Nov-15-21 06:00AM
Nov-09-21 08:00AM
Oct-25-21 10:00AM
Oct-18-21 07:00AM
Oct-13-21 07:00AM
Sep-02-21 04:05PM
Aug-16-21 06:30AM
Aug-12-21 08:00AM
Jul-26-21 08:13AM
Jun-14-21 06:30AM
Jun-09-21 06:30AM
May-25-21 10:46AM
May-24-21 06:30AM
06:15AM
May-18-21 08:00AM
06:30AM
Apr-20-21 07:00AM
Mar-31-21 06:30AM
05:45AM
Mar-24-21 06:30AM
Mar-02-21 07:00AM
Mar-01-21 07:00AM
Feb-02-21 06:30AM
Jan-04-21 06:30AM
Dec-09-20 04:30PM
Dec-02-20 06:21PM
Nov-16-20 06:30AM
Nov-12-20 06:30AM
06:15AM
Nov-10-20 04:30PM
Nov-05-20 06:30AM
Nov-04-20 06:30AM
Oct-21-20 06:30AM
Oct-05-20 06:30AM
Sep-10-20 04:30PM
Sep-02-20 06:30AM
Aug-13-20 06:30AM
Aug-12-20 12:17PM
Aug-06-20 07:00AM
May-14-20 06:30AM
May-11-20 05:00PM
Apr-07-20 04:05PM
Mar-31-20 06:30AM
Mar-26-20 06:30AM
Mar-20-20 08:00AM
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OrbiMed Israel BioFund GP Limi10% OwnerMay 15 '24Sale0.3824,3449,28013,773,653May 20 04:39 PM
Oron AssafChief Business OfficerNov 29 '23Sale0.3710,9144,0720Dec 01 04:46 PM